Table 2.
Clinical characteristics of primary gastrointestinal diffuse large B-cell lymphoma patients
| Clinical characteristics | n | DP | Non-DP | χ2 | P |
| Patients | 60 | 18 | 42 | ||
| Age (yr) | 2.534 | 0.111 | |||
| ≤ 60 | 34 | 13 | 21 | ||
| > 60 | 26 | 5 | 21 | ||
| Gender | 0.051 | 0.821 | |||
| Male | 32 | 10 | 22 | ||
| Female | 28 | 8 | 20 | ||
| Primary site | 0.013 | 0.908 | |||
| Stomach | 36 | 11 | 25 | ||
| Intestinal | 24 | 7 | 17 | ||
| Lugano staging system | 22.781 | < 0.0001 | |||
| I-II2 | 36 | 2 | 34 | ||
| IIE-IV | 24 | 16 | 8 | ||
| LDH | 0.207 | 0.649 | |||
| Normal | 34 | 11 | 23 | ||
| Elevated | 26 | 7 | 19 | ||
| B symptoms | 0.277 | 0.599 | |||
| Positive | 7 | 1 | 6 | ||
| Negative | 53 | 17 | 36 | ||
| IPI | 2.286 | 0.131 | |||
| 0-2 | 50 | 13 | 37 | ||
| 3-5 | 10 | 5 | 5 | ||
| Pathological type | 2.188 | 0.139 | |||
| Non-GCB | 48 | 17 | 31 | ||
| GCB | 12 | 1 | 11 | ||
| CD10 status | 0.013 | 0.908 | |||
| Positive | 36 | 117 | 25 | ||
| Negative/NA | 24 | 17 | |||
| CD5 status | 2.265 | 0.127 | |||
| Positive | 49 | 13 | 36 | ||
| Negative/NA | 11 | 5 | 6 | ||
| CD20 status | 0.207 | 0.649 | |||
| Positive | 34 | 11 | 23 | ||
| Negative/NA | 26 | 7 | 19 | ||
| Anemia | 0.003 | 0.955 | |||
| Present | 33 | 10 | 23 | ||
| Absent | 27 | 8 | 19 | ||
| Treatment | 2.017 | 0.156 | |||
| ST + CT | 51 | 13 | 38 | ||
| ST + CT + RT | 9 | 5 | 4 | ||
| Therapeutic evaluation | |||||
| CR | 48 | 9 | 39 | 11.910 | 0.001 |
| PR/SD/PD | 12 | 9 | 3 | ||
DP: MYC/BCL-2 protein double positive; Non-DP: Non-MYC/BCL-2 protein double positive; NA: Not available; ST: Surgery; CT: Chemotherapy; RT: Radiotherapy; CR: Complete remission; PR: Partial remission; SD: Stable disease; PD: Progressive disease.